ABSTRACT
During the year 1993-1994, 73 renal transplant cases have been screened for the presence of anti-HLA antibodies using the standard lymphocytotoxicity assay. Amongst the 9 related transplantations with 100% negative crossmatch 6 were successful. About 8.2% of the patients had a shift from positive to negative crossmatch. It was observed that an increased number of transfusions (ranging from 3 to 21) in males and females yielded negative crossmatches. In females, however, owing to various factors such as pregnancies, parity and infections, varied percentages were observed with different donors. The crossmatches in diabetics and hypertensive patients suggest no particular correlation and probably have no role in the outcome of the assay.
Subject(s)
Blood Transfusion , Cytotoxicity Tests, Immunologic , Female , HLA Antigens/immunology , Histocompatibility Testing , Humans , Immunization , Isoantibodies/analysis , Kidney Transplantation/immunology , Male , PregnancyABSTRACT
The present study was conducted to evaluate and compare the specific cellular responses of children vaccinated with three different strains of BCG. The study comprised of normal children with normal weight and normal general responses (PHA) to in vitro leukocyte migration inhibition test (LMIT). The three strains of BCG under study were Japan-BCG, Glaxo-BCG and Madras-BCG. One hundred children were selected at random from each group. The mean ages of these infants were 9.9 +/- 9.5, 9.8 +/- 7.6 and 9.8 +/- 8.3 weeks, respectively. Six weeks after vaccination, the diameter (in mm) of induration at the vaccination site was measured. Three months after vaccination, in vitro LMIT was performed against PPD tuberculin antigen. This test was done again after 3 months in all the children who tested negative. The mean value of the diameter of the Glaxo-BCG group (10.0 +/- 13.5 mm) was significantly higher (p < 0.05) than the mean values of Japan-BCG (9.10 +/- 3.9 mm) and Madras-BCG (8.38 +/- 4.1 mm). The mean LMI values were similar in all the three groups. There was no correlation between the in vitro and in vivo parameters. The number of children positive to LMI (PPD) were 59, 58 and 63, for the Madras, Japan and Glaxo-BCG groups, respectively. A total number of 91, 91 and 95 were positive to LMIT at the end of 6 months after BCG in the Madras, Japan and Glaxo-BCG groups, respectively. The observations suggested that there were no major differences between the three strains of BCG in their capacity to induce cellular responses.
Subject(s)
Analysis of Variance , BCG Vaccine/administration & dosage , Evaluation Studies as Topic , Female , Humans , Infant , Male , Tuberculosis/immunology , VaccinationABSTRACT
The objectives of this study were to evaluate whether a newborn or a neonate is capable of responding immunologically after BCG vaccination and to find out if this immunity persists for one year. Normal infants aged between 0 days-3 months brought to immunization centre were included in the study. In vitro leukocyte migration inhibition test was performed in these children using Phytohemagglutinin and purified protein derivative (PPD). They were grouped based on their age at vaccination, their LMI values and on the time interval after vaccination. The mean values of % LMI (PPD) in all the age groups were positive and there were no significant differences between the newborns, the neonates and other groups. The values were positive and comparable even after 12 months in all the groups. The percentage of infants with positive or negative values to LMI (PHA) and negative values to LMI (PPD) were also comparable at different time intervals in different age groups. The results suggest that newborns or neonates are as capable of eliciting a positive immune response after BCG vaccination, as older infants and the practise of vaccinating a child at birth could be continued.